Geiser Pharma

What Geiser Pharma does

Geiser Pharma S.L.U. is a privately held pharmaceutical development company headquartered in Mutilva (Navarra), Spain, founded in 2007/2008 as a subsidiary of the diversified Grupo Qube. The company focuses on value-added niche generics and innovative pharmaceutical forms, organized into four therapeutic-area product categories: Rx niche generics (e.g., Dicloxacillin Sodium, Penicillin V, Mercaptopurine, Disulfiram, Levetiracetam Solution, Ethylmorphine, Carbocisteine Lysine), OTC products (lozenges, sprays, sticks, gummies, and soft capsules for sore throat, pain, motion sickness and nicotine replacement), healthcare/medical devices (denture adhesive, cleaning tablets, mosquito repellent bracelet, glycerol syrup), and new development dossiers currently in pipeline. Geiser holds 240+ marketing authorizations and 104+ active registrations worldwide, including a first-of-its-kind marketing authorization for a medicated chewing gum dosage form.

The company's technology stack spans the full pharmaceutical development value chain: API selection and characterization, comparative dissolution profiles, galenic development, analytical development, scale-up and pilot batch manufacturing, quality control, and ICH-stability studies. Underlying delivery-system expertise covers sprays, lozenges, sticks, gummies, soft capsules, effervescent tablets, medicated chewing gums and topical gels, with the SPRAY-TECH innovation project subsidised by the Government of Navarre in 2025 to develop more efficient and sustainable spray manufacturing.

Geiser operates as a B2B licensing-and-services platform, monetising through (a) licensing-out a portfolio of EU-CTD dossiers to pharmaceutical companies that commercialise under their own private label under multi-year agreements, and (b) contract research and co-development project management for third parties covering market evaluation, R&D, regulatory affairs, scale-up and supply. Pricing is not publicly disclosed but is structured as flexible licensing and supply models on a quote basis. The customer base is enterprise pharma — including Sanofi, Teva, Bayer, Stada, Viatris, Polpharma, Biogaran, Farmak, Kern Pharma, Adamed, Cinfa, Pierre Fabre, Urgo and Klosterfrau — and the company sells through industry events (CPHI), direct business development, and EU/Navarra-subsidised BD programs. International operations extend to Mexico, Brazil (2023) and a China sales office. The company is led by CEO/Directora General Verónica Madrid and is part of Qube Pharma Group alongside Lozys Pharma (lozenge manufacturing), Proteus (pain-treatment R&D) and Sejmet (niche generics).

Name

Geiser Pharma

Legal name

Geiser Pharma S.L.U.

Website

https://geiserpharma.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

Geiser Pharma is a Spanish pharmaceutical development company that licenses EU-CTD dossiers and delivers contract co-development services to enterprise pharma partners worldwide, with a niche-generic, OTC and innovative drug-delivery portfolio across 240+ marketing authorizations.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Pharmaceutical development
• Niche generic drugs
• Dossier licensing services
• Contract pharmaceutical research
• OTC product development

Headquarters

HQ city

Mutilva Alta

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Licensing-out Dossier Portfolio: Wide range of pharmaceutical dossiers ready to be registered worldwide, offered under licensing and supply agreements to pharmaceutical partners. Products are commercialized under customer private label brands with high-quality EU-CTD dossiers registered in multiple countries.
2. Contract Research & Co-development: Complete management of pharmaceutical development projects including market evaluation, R&D, regulatory services, and supply chain management for third-party clients seeking specialized pharmaceutical development expertise.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Geiser Pharma develops and licenses pharmaceutical dossiers and finished formulations for prescription (RX), over-the-counter (OTC) and healthcare/medical device categories. The company primarily operates a B2B licensing-out model, offering EU-CTD dossiers registered in multiple countries and contract research/co-development services covering API selection, galenic development, analytical work, scale-up, stability studies and regulatory affairs for third-party pharmaceutical partners worldwide.

Product overview

Geiser Pharma is a pharmaceutical development company founded in 2008 in Navarra, Spain, specializing in niche generic and value-added pharmaceutical products. The portfolio is organized into three main product categories: (1) RX (prescription niche generics) covering infectious diseases, oncology, CNS, and respiratory therapeutic areas with products such as Dicloxacillin Sodium, Penicillin V, Mercaptopurine, Disulfiram, Levetiracetam Solution, Ethylmorphine, and Carbocisteine Lysine; (2) OTC (over-the-counter) spanning respiratory (lozenges, sprays), motion sickness, pain relief, women's health, CNS, and nicotine replacement therapy, including Doxylamine succinate, Hyoscine+Paracetamol, Ibuprofen, Flurbiprofen lozenges, Benzydamine products, Lidocaine sprays, Nicotine products, Carbocisteine, Glycerol syrup, and new development sprays; and (3) Healthcare/Medical Devices including denture adhesives, dental cleaning tablets, glycerol cough syrup, mosquito repellent bracelets, and propolis lozenges. In addition to its product portfolio, Geiser Pharma offers two core services: licensing-out of dossier portfolios (ready-to-register worldwide with regulatory support) and contract research co-development project management covering the full pharmaceutical development value chain. The company operates as part of Qube Group and holds over 240 marketing authorizations worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• Licensing-Out Dossier Portfolio B2B licensing-out service offering a wide range of pharmaceutical dossiers ready for registration worldwide, with EU-CTD dossiers registered in multiple countries, regulatory support and global product supply. Customers commercialize the products under their own private label brands.
• Contract Research Co-Development Projects End-to-end pharmaceutical development project management for third-party clients covering market evaluation, R&D, API selection and characterization, galenic and analytical development, scale-up and pilot batch manufacturing, quality control, stability studies, clinical studies and regulatory affairs.
• RX (Prescription) Niche Generic Portfolio Portfolio of prescription niche generic pharmaceutical products covering infectious diseases (Dicloxacillin Sodium 250/500 mg tablets, Penicillin V oral solution), oncology/immunosuppressants (Mercaptopurine 50 mg tablets), CNS treatments (Disulfiram 200/400 mg effervescent tablets; Levetiracetam 100 mg/ml oral solution) and respiratory products (Ethylmorphine antitussive solution; Carbocisteine Lysine 2.7 g mucolytic sachets).
• OTC Lozenges and Throat Products Portfolio OTC lozenges, sprays, soft capsules, sticks, mouthwash and tablets for sore throat, cough & cold, pain relief, sleep, motion sickness and nicotine replacement therapy. Includes flurbiprofen lozenges (with and without sugar), benzydamine lozenges, ambroxol lozenges, lidocaine + vitamin C lozenges, benzydamine/cetylpyridinium lozenges, propolis lozenges, lidocaine spray, benzydamine spray, flurbiprofen mouthwash, ibuprofen soft capsules, flurbiprofen sticks, doxylamine succinate tablets and sticks, hyoscine+paracetamol tablets, dimenhidrynate motion-sickness solution, nicotine spray, nicotine gummies and ibuprofen gel.
• Healthcare Products / Medical Devices Portfolio Healthcare products and medical devices including paraben-, zinc- and flavour-free denture adhesive cream, effervescent dental cleaning tablets (eliminate 99.99% of odor-causing bacteria), sugar-free glycerol syrup for dry tickly cough in children over 3 months, and a natural plant-essential-oil mosquito repellent bracelet.

Quantifiable outcome

• 240+ marketing authorizations worldwide
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Qube Pharma GroupcoreStrategic or Co-development PartnerGeiser Pharma is part of Qube Pharma Group, which includes Lozys Pharma (specialized in development, manufacturing and packaging of medicated lozenges), Proteus (specialized in R&D of high-tech pharmaceutical products for breakthrough pain treatment), and Sejmet (specialized in niche generic R&D). The group focuses on innovation and pharmaceutical development with global presence.
• Lozys PharmacoreStrategic or Co-development PartnerSister company within Qube Pharma Group specializing in development, manufacturing and packaging of pharmaceutical lozenges. Produced 17 million units in 2023 with 22% growth, implementing €5 million investment plan for consolidation, digitization and energy efficiency.
• SanofiminorChannel Partner/ Reseller/ DistributorPharmaceutical partner logo displayed on website as part of customer/client portfolio relationships
• TevaminorChannel Partner/ Reseller/ DistributorPharmaceutical partner logo displayed on website as part of customer/client portfolio relationships
• BayerminorChannel Partner/ Reseller/ DistributorPharmaceutical partner logo displayed on website as part of customer/client portfolio relationships
• StadaminorChannel Partner/ Reseller/ DistributorPharmaceutical partner logo displayed on website as part of customer/client portfolio relationships
• ViatrisminorChannel Partner/ Reseller/ DistributorPharmaceutical partner logo displayed on website as part of customer/client portfolio relationships
• Gobierno de NavarraminorOthersRegional government providing grants and support for innovation projects, competitiveness improvements, and digital business promotion. Supported SPRAY-TECH innovation project and XPANDE Digital program.
• Unión Europea (NextGenerationEU/FEDER)minorOthersEuropean Union funding through FEDER and NextGenerationEU programs supporting SME competitiveness and innovation initiatives including CPHI trade fair participation.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with deep portfolio across Rx, OTC, and specialty. Comparable as a global generic incumbent and customer-class partner for dossier licensing transactions.
• Stada Arzneimittel: Major European generic and consumer healthcare company with broad portfolio and global licensing activities. Comparable as a partner-class generic player active in OTC and niche generics across multiple European markets.
• Cinfa: Spain-headquartered generic and OTC pharmaceutical company with significantly broader product portfolio and larger scale. Comparable as a Spanish generic peer overlapping in OTC categories such as sore throat, pain, and respiratory products.
• Viatris: Global generic and specialty pharmaceutical company formed via Mylan-Upjohn combination with extensive licensing footprint. Comparable as a listed B2B partner for Geiser's dossier out-licensing activities in multiple therapeutic areas.
• Aurobindo Pharma: Indian-headquartered global generic pharmaceutical manufacturer with active licensing and dossier acquisition strategy in Europe and emerging markets. Comparable for its dossier-based expansion model targeting regulated markets.

Direct peers

• Farmak: Ukrainian pharmaceutical manufacturer specializing in generics with extensive international licensing and export footprint. Comparable for dossier-led licensing of niche generic molecules across multiple regulatory jurisdictions.
• Adamed Pharma: Polish pharmaceutical company with R&D and generic manufacturing operations, licensing dossiers internationally. Highly comparable as a mid-sized European pharma combining niche generics, development services, and out-licensing to global partners.
• Polpharma: One of the largest Polish generic pharmaceutical manufacturers with active out-licensing and contract development operations. Comparable to Geiser for its dossier-based B2B licensing model and Central European heritage.
• Kern Pharma: Spanish generic pharmaceutical company with broad portfolio and development capabilities. Directly comparable to Geiser as a Spain-based generics player with both Rx and OTC products and B2B partnerships.

Regional players

• Biogaran: French generic pharmaceutical leader, part of Servier group, with broad Rx generic portfolio. Comparable as a European generics-focused company that could serve as a licensing partner for Geiser's dossiers in the French market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/geiserpharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Geiser Pharma